European LUpuS Inception-Cohort Developing initiATivE
NCT07209540 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 700
Last updated 2025-10-07
Summary
The goal of this observational study is to learn more about how systemic lupus erythematosus (SLE or lupus) develops in the first years after diagnosis, and how patients respond to different treatments.
The main questions the study aims to answer are:
How many patients with newly diagnosed lupus reach remission or low disease activity in the first years after starting treatment?
Which biological markers (in blood or urine) can help predict treatment response, disease complications, or symptoms such as pain and fatigue?
Adults recently diagnosed with lupus (within the past 6 months) will be invited to participate. They will continue with their normal medical care, but in addition, they will take part in study visits over a 5-year period. At these visits, doctors will collect information about symptoms, treatment, and quality of life. Blood and urine samples will also be stored in a biobank for later analysis.
Around 720 patients from several European countries are expected to join the study. Because participants are included very soon after diagnosis, researchers can follow the course of lupus from the beginning, before long-term treatment or damage occurs.
By combining clinical information and biological samples, researchers hope to identify new ways to understand lupus, improve treatment strategies, and eventually develop personalized medicine approaches. This could help future patients achieve better disease control, fewer complications, and improved quality of life.
Conditions
- Systemic Lupus Erythematosus (SLE)
Sponsors & Collaborators
-
University of Aarhus
lead OTHER
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-01
- Primary Completion
- 2029-12-01
- Completion
- 2033-07-01
More Related Trials
-
Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in Russia
NCT06759519 ·Status: COMPLETED
-
Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment
NCT07102030 ·Status: RECRUITING
-
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
NCT00000421 ·Status: COMPLETED ·Phase: PHASE2
-
Psycho-social Consequences of Systemic Lupus Erythematosus
NCT03913754 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
NCT03161483 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Systemic Lupus Erythematosus
NCT00001372 ·Status: RECRUITING
-
Identifying New Therapeutic Targets for Lupus Treatment
NCT03921398 ·Status: COMPLETED
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
NCT06064929 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
NCT03724916 ·Status: COMPLETED ·Phase: PHASE1
-
A Non-drug Study Profiling Cutaneous Lupus
NCT01923415 ·Status: COMPLETED
-
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
NCT00137969 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Weaning of Immunosuppression in Nephritis of Lupus
NCT01284725 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
NCT02547922 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
NCT02034344 ·Status: COMPLETED
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
Anti-nucleosome B Lymphocytes in Lupus
NCT01889654 ·Status: TERMINATED
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289 ·Status: RECRUITING ·Phase: PHASE2
-
Atacicept Demonstrating Dose RESponSe
NCT01440231 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
NCT04058028 ·Status: COMPLETED ·Phase: PHASE2
-
Systemic Lupus Erythematosus Exercise Program
NCT03942718 ·Status: COMPLETED ·Phase: NA
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Long-Term Outcomes in SLE at Peking University People's Hospital
NCT07005479 ·Status: RECRUITING
-
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
NCT00624338 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
NCT01405196 ·Status: COMPLETED ·Phase: PHASE2